Shares of Arcturus Therapeutics Ltd (NASDAQ:ARCT) have earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $12.00.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 19th. ValuEngine downgraded shares of Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 8th. Brookline Cap M reiterated a “buy” rating on shares of Arcturus Therapeutics in a research note on Thursday, September 27th. Finally, WBB Securities upgraded shares of Arcturus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 20th.
ARCT opened at $5.85 on Thursday. Arcturus Therapeutics has a fifty-two week low of $4.78 and a fifty-two week high of $10.45. The firm has a market cap of $67.15 million, a price-to-earnings ratio of -1.66 and a beta of 1.80.
Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.04. The business had revenue of $3.42 million for the quarter, compared to analyst estimates of $3.75 million. Equities analysts forecast that Arcturus Therapeutics will post -1.9 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in shares of Arcturus Therapeutics by 91.7% during the third quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock valued at $148,000 after acquiring an additional 8,008 shares during the period. BlackRock Inc. bought a new position in shares of Arcturus Therapeutics during the second quarter valued at $169,000. Worth Venture Partners LLC bought a new position in shares of Arcturus Therapeutics during the third quarter valued at $290,000. Finally, ARK Investment Management LLC lifted its holdings in shares of Arcturus Therapeutics by 61.2% during the second quarter. ARK Investment Management LLC now owns 533,773 shares of the biotechnology company’s stock valued at $4,526,000 after acquiring an additional 202,608 shares during the period. 10.09% of the stock is owned by institutional investors.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Further Reading: What are the Benefits of Index Funds?
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.